H.C. Wainwright has begun coverage on Cidara Therapeutics (CDTX, Financial), offering a Buy rating and setting a price target of $41. The company is making strides with CD388, its lead drug candidate designed to combat all strains of influenza A and B through a unique drug-Fc conjugate approach.
The analyst highlights the significant gap in current influenza treatments, noting that existing vaccines and antiviral options often fall short for high-risk groups. This positioning of CD388 could meet a crucial market need, which may enhance its potential impact in the healthcare landscape.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Cidara Therapeutics Inc (CDTX, Financial) is $55.43 with a high estimate of $140.00 and a low estimate of $35.00. The average target implies an upside of 150.81% from the current price of $22.10. More detailed estimate data can be found on the Cidara Therapeutics Inc (CDTX) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Cidara Therapeutics Inc's (CDTX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cidara Therapeutics Inc (CDTX, Financial) in one year is $0.08, suggesting a downside of 99.64% from the current price of $22.1. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cidara Therapeutics Inc (CDTX) Summary page.
CDTX Key Business Developments
Release Date: May 08, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Cidara Therapeutics Inc (CDTX, Financial) is advancing its CD 388 program, which aims to revolutionize influenza prevention with a novel drug conjugate.
- The CD 388 drug has shown promising preclinical data, published in Nature Microbiology, highlighting its potential as a universal antiviral for influenza A and B.
- The phase 2B Navigate study for CD 388 is underway, with dosing completed for over 5,000 subjects, and top-line data expected by the end of June.
- Cidara Therapeutics Inc (CDTX) is in discussions with the FDA to potentially evaluate statistical significance in their phase 2B study due to the severity of the flu season.
- The company plans to initiate a phase 3 study in high-risk populations, focusing on those underserved by current vaccines and antivirals, in the spring of 2026.
Negative Points
- Cidara Therapeutics Inc (CDTX) is currently a non-revenue generating company, which may pose financial sustainability challenges.
- The Navigate study was not initially powered for statistical significance, which could impact the robustness of the results.
- There is uncertainty regarding the pricing and market size for CD 388, with discussions on potential pricing above initial estimates.
- The company is still finalizing the definition of high-risk patient populations for its phase 3 study, indicating ongoing strategic planning.
- The final data for the phase 2B study, including pharmacokinetic data, will not be available until September, delaying comprehensive analysis.
